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PREGNANCY AMONG WOMEN WITH CONGENITAL HEART DEFECTS: 
OUTCOMES FOR MOTHER AND CHILD 
MICHELLE ZIPPORA LEISNER 
 
ABSTRACT 
 Congenital Heart Defects (CHDs), structural heart defects that are present at birth, 
are prevalent in approximately 1% of live births. While, historically, the presence of such 
defects was associated with a heightened risk of mortality, advances in medicine have 
allowed nearly 85% of individuals with CHDs to live into adulthood. As such, many of 
these individuals are reaching reproductive age and are becoming pregnant. In order to 
understand the implications of pregnancy among women with CHDs, a literature review 
was undertaken in order to elucidate the conditions that may present to the mother, as a 
product of the underlying defect, as well as to discern the impact of a maternal CHD on 
the child.  
 Pregnancy induces hemodynamic alterations, such as an increase in stroke volume 
and heart rate (and thus cardiac output), and brings about an increase in blood volume. In 
populations with CHD, these hemodynamic changes may induce particular risks to the 
mother, as her cardiac condition may obstruct her ability to cope to with the heightened 
stress on the heart. Moreover, given that the heart may not function in an ideal manner, a 
less than ideal environment is present in-utero.   
Women with CHD suffer from elevated cardiovascular and obstetric 
complications, with the risk of some cardiovascular events extending into the post-partum 
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period. During pregnancy, approximately 11% of women with CHD will experience a 
cardiovascular complication; this risk is highest among those with complex forms of the 
defect. Arrhythmia, specifically, is the most common complication, and will occur in 
4.5% of pregnancies. Heart failure is also frequent, occurring in 4% to 5% of 
pregnancies, with the highest risk presenting in those patients with Eisenmenger 
syndrome and those with cyanotic forms of CHD. Pulmonary edema and thrombolytic 
events are also present in this population with a higher prevalence than in a healthy 
pregnant population. In the 6-month period after delivery, 12% of women with CHD will 
experience a cardiac event, with arrhythmia and heart failure as the most common 
complications.   
Obstetric complications occur in approximately 5% of pregnancies among women 
with CHDs, with 11% experiencing premature labor, 8.4% experiencing post-partum 
hemorrhage and 5.5% experiencing pregnancy-induced hypertension. Miscarriage occurs 
in 15% of pregnancies, with a dose-response type relationship associated with the 
severity of the underlying defect, as miscarriage occurs in up to 66% of pregnancies in 
those with Fontan palliation. Premature rupture of membranes occurs in 3.5% of 
pregnancies, with half of these cases occurring to patients with transposition of the great 
arteries. Termination of pregnancy also occurs in 5% to 8% of pregnancies, given high 
risk of complications to both mother and fetus. While preeclampsia is expected to occur 
in approximately 2-3% of pregnancies, this risk does not exceed what occurs in a healthy 
population.  
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With regard to the impact of maternal CHD on the fetus, events occurring to the 
fetus/neonate include preterm delivery, small for gestational age, respiratory distress 
syndrome, intraventricular hemorrhage, and neonatal death. Between 1.5% and 2% of 
pregnancies will terminate in fetal mortality. Premature birth is likely in 12% to 20% 
births, with of 8% of neonates born as small for gestational age. Moreover, 3.5% of 
children born to mothers with CHD will present with CHD, themselves. Long-term 
effects of maternal CHD are not well-described.  
Despite these complications, pregnancy among women with CHD is well-
tolerated and only in very few cases of those presenting with severe defects, is pregnancy 
counter-indicated. However, in order to mitigate risks, pre-pregnancy counseling is 
recommended in all women with CHD, regardless of severity of the defect. Counseling 
should include an overview of the form of defect, any surgical or medicinal interventions 
undertaken in response to the defect, an echocardiography, an exercise stress test, among 
other evaluations. Monitoring of the pregnancy should continue throughout gestation and 
delivery should occur in a specialized care facility and the mother and fetus should be 
monitored by a consortium of cardiologists, obstetricians, anesthesiologists, midwives. 
Monitoring of the mother should extend into the post-partum period until any 
cardiovascular or hemodynamic pregnancy-related alterations have returned to normal.  
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BACKGROUND 
 
Overview: Congenital Heart Defects 
 
Congenital Heart Defects (CHDs) represent all forms of structural heart disease, present 
at birth. CHDs are the most common congenital condition at a rate of 1% of all live 
births, with variation in this estimate by region.1-3 Approximately 1.35 million children 
are born with CHDs every year, worldwide.1  
 Congenital heart defects vary in structure, severity and physiological impact, and 
thus, in order to better understand and treat these conditions, are categorized with regard 
to these constructs. With regard to severity, CHDs range from mild, indicating that the 
condition may be asymptomatic and does not require surgery, to complex, indicating 
severe risk of mortality and necessary surgical interventions (Appendix A). Prevalence 
estimates conclude that approximately 45% of individuals present with a mild form of 
CHD, 40% present with a moderate condition, and 15% are diagnosed with a complex 
defect, and even within these categories, prevalence of specific CHDs vary.4   
 These defects may lead to severe consequences, both with regard to morbidity and 
mortality. Furthermore, these health consequences may manifest at different points in 
life, starting in the fetal period and impactful throughout adulthood. 
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The Normal Heart, Structure and Function 
 In order to understand the impact of a CHD, with regard to physiological and 
pathological interferences within the human body, an appreciation of how a normal heart 
functions must be undertaken. A physiologically normal heart consists of two atriums, 
two ventricles and valves which separate each of these cardiac chambers (Figure 1). 
Between each of these chambers lies a wall of tissue, known as the septum; specifically, 
the component of the septum that lies between the right and left atrium, or upper 
chambers of the heart, is known as the atrial septum, while the part of the septum which 
lies between the right and left ventricles is known as the ventricular septum. 
 
Figure 1. The anatomy of the normal heart.5 In normal circulation, deoxygenated 
blood from the body enters the right atrium, flows through the tricuspid valve and into the 
right ventricle, where it is subsequently pumped through the pulmonary artery into the 
lungs. Oxygenated blood then returns, entering the left atrium, passing through the mitral 
valve and into the left ventricle, a more muscular ventricle than the right, where it is 
pumped through the aorta to begin circulation through the body.  
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During  typical circulation, deoxygenated blood enters the right atrium via the 
superior and inferior vena cava (among other vessels), passes through the tricuspid valve 
and fills the right ventricle; during contraction, this blood moves through the pulmonary 
valve and into the lungs for oxygenation. Oxygenated blood then enters the left atrium 
via the pulmonary veins and crosses the mitral valve to fill the left ventricle and, upon 
contraction, moves through the aorta to supply to body with oxygenated blood.  
 
Most Common Congenital Heart Defects  
 A comprehensive list of the definitions of the most common CHDs can be found 
in Appendix A. However, a brief overview of a few CHDs will be given, in order to 
introduce specific CHDs which are severe and/or prevalent and thus important to 
understand prior to introducing the main focus of this thesis.  
 Atrial septal defects (ASD), which present with a prevalence of 1.6/1,000 live 
births, and is thus the 2nd most common form of CHD, is a defect in which there is a gap 
in the atrial septum (Figure 2a).1 As the right atrium typically has a slightly lower 
pressure than the left atrium, oxygenated blood will move left to right to mix with the 
expected deoxygenated blood returning to the heart from the body. This fills the right 
atrium with additional blood and this increased volume of blood may cause harm to both 
the heart and the lungs.  
Ventricular septal defects (VSD), the most common CHD with a prevalence of 
2.62/1,000 live births, are similar to ASDs in that the physiological disruption is caused 
by additional blood flow from the left side of the heart entering the right side by way of a 
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gap(s) in the ventricular septum (Figure 2b).1 As is the case with the ASDs, this allows 
oxygenated blood to “recycle” through the pulmonary arteries and into the lungs. 
However, contrary to the ASDs, this increase of blood flow to the lungs is by way of the 
high pressure generated in the left ventricle, which causes direct, and eventually 
irreversible if unrepaired, lung damage. Specifically, muscular VSDs are prevalent in 
27.5 out of 10,000 live births and perimembranous VSDs are prevalent in 10.6 out of 
10,000 live births.6  
 The aorta is the pathway out of the heart for oxygenated blood to enter 
circulation. Coarctation of the aorta (CoA), prevalent in 0.34 per 1,000 live births,  occurs 
when there is a narrowing of the aorta, regularly at the insertion point for the ductus 
arteriosus (Figure 2c).1  Given that this is the sole path for blood to enter circulation, an 
obstruction of this form may reduce the volume of blood flow to areas beyond the site of 
the coarctation. This may limit blood flow to the degree that organ damage can occur in a 
matter of hours if left untreated. Additionally, since the heart attempts to overcome the 
obstruction by generating higher perfusing pressure, there is eventual stress on the heart 
that may become irreversible in a matter of days, which can ultimately become fatal.7 
 Tetralogy of Fallot (ToF) is a more complex CHD, which is diagnosed by the 
presence of four specific cardiac defects occurring within a singular heart (Figure 2d). 
These four defects are: VSD, an enlarged aorta which overrides both ventricles such that 
blood may enter it from both the right and left ventricle, pulmonary stenosis (narrowing), 
and right ventricle hypertrophy. The degree of pulmonary stenosis largely determines the 
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urgency required for intervention.8 Tetralogy of Fallot is prevalent in 0.34 per 1,000 live 
births.1 
 Transposition of the great arteries (TGA) occurs when the main larger vessels 
involved in oxygenation and distribution of blood are located opposite to their normal 
physiological placement. Specifically, the pulmonary artery arises from the left ventricle 
while the aorta arises from the right ventricle (Figure 2e). The end result is that 
deoxygenated blood returns to the body without the benefit of newly acquired oxygen, 
while the properly oxygenated blood simply returns to the lungs. This CHD, prevalent in 
0.31/1,000 live births, is not compatible with life without intervention in the first days of 
life.1  
 
 
 
 
 
 
 
 
 
 
 
 
 6 
 
 
a. Atrial Septal Defect (ASD)9 b. Ventricular Septal Defect (VSD)10 
  
c. Coarctation of the Aorta (CoA)11 d. Tetralogy of Fallot (ToF)12 
  
e. Transposition of the great arteries (TGA)13 
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Figure 2. An Overview of Common Congenital Heart Defects. Atrial Septal Defects 
(ASDs) (panel a) occur when a gap in the septum of the atria persists, allowing for 
oxygenated blood to mix with deoxygenated blood. Ventricular Septal Defects (VSDs) 
(panel b) occur when the ventricular septum is disrupted such that blood moves in a 
similar fashion to ASDs. In Coarctation of the Aorta (CoA) (panel c), the aorta is much 
narrower than in a healthy heart, obstructing the blood from entering into systemic 
circulation causing elevated pressure in the heart. In tetralogy of Fallot (ToF) (panel d) 
includes a series of four defects, VSD, an enlarged aorta which overrides both ventricles 
such that blood may enter it from both the right and left ventricle, pulmonary stenosis 
(narrowing), and right ventricle hypertrophy. In transposition of the great arteries (panel 
e) the aorta extends from the right ventricle while the pulmonary artery arises from the 
left ventricle such that, without surgical interventions, deoxygenated blood re-enters 
circulation and oxygenated blood remains in a pulmonary-cardiac loop.  
 
Categorization of CHDs 
 While categorizing CHDs into simple categories such as mild, moderate and 
severe can suggest the nature of their physiological impact, and thus, the prognosis 
specific to each condition, alternative categorizations of CHDs exist, each developed 
relative to the goals of the categorization. 
 One example is the use of a physiological form of categorization, which yields 
categories such as: Left to Right Shunts, Cyanotic CHD, Left Heart Obstructive Defects, 
Right Heart Obstructive Defects, and Conotruncal defects. This categorization format 
allows for insight into the mechanisms of the defect and the potential downstream effects 
of the deformity, however this categorization does not necessarily indicate severity or the 
nature of the impact on the individual. As a result, other classifications exist that focus on 
the end result of the defect. One such categorization is the New York Heart Association 
(NYHA) classification of heart failure. This classification has been utilized in patients 
with all forms of cardiac disease to describe the functional capacity of these individuals. 
This categorization allows for an understanding of the impact of the defect on an 
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individual’s life in a fashion that can be measured, directly, with specific attention to how 
an individual is able to respond to physical activity (Table 1; Table 2)  
 
Table 1. New York Heart Association Classification of Functional Capacity (How 
a patient feels during physical activity)14  
Class Functional Capacity  
I No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, 
dyspnea (shortness of breath). 
II Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, 
palpitation, dyspnea (shortness of breath). 
III Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, 
palpitation, or dyspnea. 
IV Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any 
physical activity is undertaken, discomfort increases. 
 
  
 Additionally, CHDs can be classified into those which are cyanotic or acyanotic. 
Cyanosis is a bluish discoloration of the skin, and is either peripheral (affecting lips, 
extremities, nailbeds, and eyelids) or central (affecting all other skin surfaces). Cyanosis 
is caused by supply of deoxygenated blood or poor circulation.15 Central cyanosis is 
associated with hypoxia, a condition in which insufficient levels of oxygen persist within 
tissues of the body. Typical acyanotic lesions include VSD, ASD, atrioventricular canal 
Table 2. New York Heart Association Classification of Heart Disease by Objective 
Assessment14  
Class Objective Assessment 
A No objective evidence of cardiovascular disease. No symptoms and no limitation in ordinary physical 
activity. 
B Objective evidence of minimal cardiovascular disease. Mild symptoms and slight limitation during 
ordinary activity. Comfortable at rest. 
C Objective evidence of moderately severe cardiovascular disease. Marked limitation in activity due to 
symptoms, even during less-than-ordinary activity. Comfortable only at rest. 
D Objective evidence of severe cardiovascular disease. Severe limitations. Experiences symptoms even 
while at rest. 
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defect, patent ductus arteriosus, aortic stenosis and CoA; typical cyanotic defects include 
ToF and TGA.16 Categorizing CHDs with regard to their cyanotic or acyanotic effects is 
an important component in determining the pathophysiological impact of a CHD, given 
the negative consequences associated with hypoxia.17  
 
Physiological Implications of CHD 
 As previously described, the heart functions in a circuit, such that deoxygenated 
blood is pumped into the lungs to become oxygenated and the oxygenated blood is then 
returned to the left side of the heart to be circulated throughout the body. Thus, the heart 
can be seen as two parallel circuits: the right side ensuring oxygenation of blood while 
the left side establishes the circulation of oxygenated blood throughout the entire body.  
 Shunts, which include ASD, VSD and others, are an abnormal connection 
between these two circuits, permitting the mixing of oxygenated and deoxygenated 
blood. For example, a right-to-left shunt allows for deoxygenated blood to enter the left 
side of the blood, thereby mixing with oxygenated blood and entering into circulation 
causing relative amounts of cyanosis. The eventual hypoxia may cause irreversible organ 
damage. 18  
 The cardiovascular system has also been likened to a singular circuit, specifically, 
with resistors (vessels) in series and in parallel and a current (circulation of blood) 
running through them. Given this metaphor, obstructive lesions, such as pulmonary 
stenosis or aortic stenosis, produce a particular, distinct obstacle for circulation by 
impacting the conditions within the circuit itself. For example, in aortic stenosis, the aorta 
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is narrowed which cause increased resistance across the aorta—in physiological terms, 
the afterload on the ventricle is increased. In response to this, ventricular hypertrophy, 
reduced chamber compliance, a reduced stroke volume, and higher filling pressures in the 
atrium all may occur.19 The details of the heterogeneous forms of pathophysiological 
disruption caused by complex CHDs require extensive medical and physiological 
explanation, and thus, go beyond the scope of this thesis.20   
 
Risk Factors for CHD  
There are both genetic and environmental causes associated with CHD. With regard to 
genetics, a variety of genetic alterations have been found to be associated with increased 
risk of CHD. Individuals with chromosomal aberrations, such as trisomy 13, trisomy 18, 
trisomy 21 and Turner Syndrome (one X chromosome present versus the normal two sex 
chromosomes), all have an increased risk of CHD; in fact, in almost all cases of trisomy 
13 and trisomy 18, CHD is diagnosed.21 Furthermore, singular genetic mutations, may 
also give rise to CHD; mutations in transcription factors which regulate cardiac 
development in-utero, have been identified as one of the primary genetic causes 
underpinning the development of  CHD.22  However, our understanding of the genetic 
mechanisms by which CHD arises is incomplete. Familial clustering of CHD has, 
however, been described, but, interestingly, identical mutations in a given family give 
rise to distinct forms of CHD.21, 22 Moreover, while specific genetic mutations have been 
identified, the mechanisms by which these mutations disrupt the process of cardiogenesis 
is still unclear.22 
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 Environmental factors associated with an increased risk of CHD relate 
predominantly to the in-utero conditions to which the fetus is exposed. Maternal health, 
both prior to the pregnancy and during the pregnancy may, therefore, impact the risk of 
CHD. Certain maternal exposures may both increase or reduce the risk of CHD in the 
child. For example, folic acid is well described to have a protective impact if maternal 
levels are normal (there is no evidence of additional protection from supratherapeutic 
levels). Other medications, such as ibuprofen, may increase the risk of particular CHDs 
by approximately 2-fold.23 A near 4-fold increase in risk of congenital cardiovascular 
malformations has also been described among infants whose mothers used angiotensin 
converting-enzyme inhibitors (ACE-inhibitors) versus mothers who did not use any 
hypertensive medications, in the first trimester.24  
 The most well described maternal environmental exposure associated with an 
increased rate of CHD is maternal glycemic dysregulation, best represented by maternal 
diabetes mellitus.25-27 This impact of glycemic dysregulation is evident even in those 
exposed to maternal obesity, even without diabetes. Several studies have documented a 
dose-response relationship of a heightened risk relative of CHD to the degree of maternal 
obesity.28, 29  
Mortality from CHD 
Given the physiological importance of a normal and fully-functional heart, CHDs are 
associated with a heightened risk of mortality. Specifically, mortality is highest for 
infants aged less than 1 year, with infant mortality accounting for 48.1% of mortality that 
is associated with CHD.30 
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The severity and complexity of CHD impacts the likelihood of survival (Figure 
3). Supporting the concept that severity and survival are closely linked, a Norwegian 
study described the 1-year cumulative mortality proportion as 17.4% for children with 
severe CHDs, whereas it was 3.0% for non-severe cases.31 Furthermore, baseline analysis 
of a German register-based study indicated that of those 52.9% and 24.4% of the cohort 
who were alive at baseline presented with moderate and severe defects, respectively, 
whereas among those that were deceased at baseline, 26.4% and 59.8% had been 
diagnosed with moderate and severe CHDs. 32 Thus, individuals with more severe CHDs 
have a reduced lifespan as a product of their condition.  
  
Figure 3. Median age (in days) at death resulting from Congenital Heart Defects, 
stratified by the underlying cause of death (United States, 1999 - 2006). 30 Age of 
death varies dependent on underlying defect, with an average age at death of 365 days (1 
year). However, with those with Ventricular Septal Defect and Atrial Septal Defect, the 
most common simple defects, life expectancy is 44 and 71 years, respectively. For more 
complex defects, such as coarctation of the aorta and transposition of the great arteries, 
life expectancy is only two months.  
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Changes in Mortality  
 Fortunately, advances in medical treatments, surgical techniques as well as 
heightened ability to detect CHD in-utero, have decreased the rate of mortality among 
individuals with CHD with the largest decrease in mortality among infants.31, 33 When 
evaluating the cause of death among infants less than 1 year of age, CHDs accounted for 
92 deaths per 100,000 between 1979 and 1981, and dropped to ~56 deaths per 100,000 
between 1995 and 1997 in the United States.34 An additional study reported a further 
decrease in mortality across all age groups between 1999 and 2006, with a decrease in 
mortality of 17.3% among infants (<1 year), 21% for children aged 1 to 4, and 36.1% for 
children between ages 5 and 17; for adults, the decrease was greatest among those aged 
65 and older, with mortality decreasing 42.7% over this time period.30 As a result, there is 
confidence that individuals with CHDs are living longer presently than historical 
evidence suggests, and that many survive into adulthood.   
 
Comorbid Conditions Associated with CHD: Cardiac 
 Given the increase in survival across the CHD population, an epidemiological 
shift has occurred, from a population with shortened life-expectancies to a population 
with longer lifespans but developing a greater number of cardiac and non-cardiac 
complications.35  
 Cardiovascular conditions occur at a higher frequency among patients with CHDs 
than in the general population, with many of these complications evolving from the lesion 
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itself or from the surgical interventions utilized to correct or reduce the impact of the 
lesion.4 Arrhythmias are a good example of the common comorbid conditions that arise 
in patients with CHD.36, 37 Arrhythmias can occur in all patient populations with CHD, 
with highest prevalence in patient populations with either moderate or complex CHDs.4 
Malformation in CHD may alter structures associated to electrophysiological regulation, 
giving rise to irregular heart rhythms, or the arrhythmia may be an acquired condition the 
result of injury or physiologic exposure, such as high afterload or a cyanotic 
environment.4  Arrhythmias can may themselves contribute to an array of additional 
complications, including stroke, which is associated with a high risk of mortality.38, 39  
 Congenital heart defects, as well as the surgeries associated with palliation or 
repair of the defect, are a risk factor for infective endocarditis (IE)1. Infective 
endocarditis is an infection of the heart and is often a life-threatening condition. 
Congenital Heart Defects of the leading risk factors for pediatric IE in the Western 
world.40, 41 A population-based study undertaken in Oregon found that the incidence of IE 
was 1.3% for ToF, 2.7% for isolated VSD and 3.5% for CoA, with the highest incidence 
occurring among those with aortic stenosis (13.3%).42 Conversely, among cases of adult 
endocarditis, a congenital heart defect is found in approximately 11% of cases.43 Thus, 
the association between CHD and IE is of utmost importance, and merits education about 
the potential use of prophylaxis in this population, given that IE is associated with high 
levels of mortality. 41, 42   
                                                 
1 Infective endocarditis: an infection of the endocardium, or the innermost layer of the 
heart brought on by bacteria entering the heart; infection occurs most frequently in the 
valves of the heart. 
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 Given the potential for stress on the heart muscle, heart failure (HF) is a common 
sequela of CHD. Even in a population with simple types of CHD, HF is the most 
common critical cardiac morbidity to occur in an adult population.44 In a Taiwanese 
nationwide retrospective cohort study, the risk of HF is increased 13-fold in those with 
CHD in comparison to those without (adjusted HR, 13.2; 95% CI, 10.1-17.2).45 
Moreover, severity of underlying heart conditions increases risk of HF in a dose-response 
relationship, as a study which included pregnant women with all forms of heart disease 
described that  1.2%, 5.6%, 19% and 54%  of those that fall into WHO risk categories of 
1, 2, 3 and 4, respectively, presented with HF during pregnancy.46 With regard to the 
association between CHD and HF, several hypotheses have been proposed. One 
hypothesis suggests that the co-existence of CHD and HF in a given individual may be 
due to either monogenetic or polygenetic disruptions, which give rise to both conditions 
simultaneously, while a second hypothesis suggests that severe CHDs (and potentially all 
forms of CHD) as well as the subsequent surgical interventions utilized in response to the 
defect, alter hemodynamics, thereby enhancing cardiac stress and increasing the risk of 
HF.45, 47 Simply, these hypotheses suggest that either both conditions arise from a single 
origin or that CHD gives rise to HF.   
 Another common association recently described is between CHD and myocardial 
infarction (MI), in which patients with CHD presented with a 2-fold increase in the risk 
of MI when compared to those without CHD.48 However, further studies should be 
undertaken to corroborate this finding.   
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Comorbid Conditions Associated with CHD: Non-Cardiac 
 Alterations in heart function can also contribute to noncardiac conditions, some of 
which are attributed to the cyanotic effects of some forms of CHD, while others are due 
to downstream pathophysiological alterations due to the lesions themselves, such as 
pressure and volume changes.35 These non-cardiac disruptions include pulmonary, renal 
and liver conditions (Figure 4).  
 Lung function is regularly impaired among individuals with CHD, with 30% of 
adults with CHD presenting with severe impairment, defined as patients with less than 
60% of the predicted forced vital capacity.2, 49 Moreover, pulmonary hypertension (PH) is 
a prevalent and dire complication of CHD, as CHDs may transmit high pressures and/or 
volumes to the pulmonary circulation, thus, leading to the development of hypertension. 
Larger cohort studies have conveyed that PH may be prevalent in approximately 3-8% of 
patients with CHD.50-52 While a minority of CHD patients may present with PH, a 4-fold 
risk in mortality has been described when both of these conditions are present in a given 
individual, compared to those with only CHD.52  
 Renal disease is significantly higher among adults with CHD than in the general 
population, with an 18-fold increase and 35-fold increase in the prevalence of renal 
dysfunction when compared to the general population, in non-cyanotic adult CHD 
patients and cyanotic adult CHD patients, respectively. 53 Of these patients, 9.3% of 
adults presented with moderate to severe (<60ml/min) reduction in their glomerular 
filtration rate (GFR) and 40.9% presenting with a mild reduction (GFR: 60 – 89 ml/min); 
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importantly, the individuals who had moderate to severe reduction in GFR had a 5-fold 
increase in mortality, even after only one-year of follow-up.53 
 The liver is another non-cardiac organ system negatively impacted by CHD. The 
etiology, as it is for other organ systems, is multifactorial. It may be due to high systemic 
venous pressure, relatively low cardiac output, hypoxia, or infections. Hepatic ischemia 
has been shown to be associated with ischemic hepatitis as well as hepatic fibrosis.54, 55 
Moreover, portal hypertension can also occur as a result of the cardiac congestion that 
occurs subsequent to the presence of CHD.55  
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Figure 4. Noncardiac complications among adults with congenital heart defects. 35 
While cardiac complications are common in patients with CHD, given an abnormal heart 
structure, the presence of the defect can also give rise to non-cardiac defects. Common 
downstream effects of CHD include PH, chronic kidney disease and cirrhosis, but 
complications extend into nearly every organ system in the human body.  
 
Treatment Strategies for CHD 
 While, historically, it was assumed that specific, simple forms of CHDs, such as 
ASD, VSD and PDA, could be cured, it is increasingly evident that all forms of CHD 
must be monitored and treated throughout the course of life.56, 57 Treatment strategies are 
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specific to the nature of each lesion, often dependent on the severity of the defect, with 
mild forms of CHD potentially requiring no treatment whereas severe cases may require 
immediate intervention. 
 Medical treatments aim to reduce stress on the heart by lowering afterload, 
modifying preload, altering blood pressure, and control heart rate and/or rhythm. In 
addition, medications are often directed at preventing potential conditions which occur 
with a higher frequency in patients with CHD, such as heart failure and embolic events 
(Table 3).  
Table 3: Commonly used medications in cases of CHD. 
Drug Use 
Angiotensin-converting enzyme inhibitor (ACE-
inhibitors) 
A class of drugs which inhibit the conversion of 
Angiotensin I to Angiotensin II, molecules which 
downstream lead to vasoconstriction; thus, these drugs 
reduce hypertension without affecting cardiac output 
Antiplatelet drugs 
 
A class of drugs which inhibit platelet aggregation, thus 
reducing the potential for thrombolytic events  
β - blockers 
 
A class of drugs which reduce blood pressure by acting 
as β-receptor antagonists on the heart 
Digoxin 
 
A drug obtained from the leaves of Digitalis lanata 
(‘foxglove) which slows down the heart rate, increases 
parasympathetic tone in the heart, and induces an 
increase in blood flow via a reduction in vascular 
resistance 58 
Diuretics 
 
A class of drugs which reduce blood pressure by 
reducing blood volume via diuresis, the increased 
production of urine 
Vitamin K antagonists 
 
A group of drugs which reduce the likelihood of blood 
clotting (and thus stroke) by inhibiting vitamin K, an 
essential molecule in the blood-clotting cascade  
  
 While medicinal treatments may reduce the potential of cardiovascular sequelae, 
their use does not remedy the underlying condition. Moreover, in complex cases of CHD, 
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use of medicinal treatment may be insufficient in isolation; some forms of CHDs, such as 
TGA and ToF, induce a high mortality rate without surgical or catheter-based 
intervention. Surgical interventions intend to palliate or treat the underlying defect and a 
multitude of surgical procedures exist to individually respond to the heterogeneous mix 
of CHD subtypes. These surgery types, and the methods involved, are beyond the scope 
of this thesis.  
 Surgery among patients with CHD is common; approximately one out of every 
five hospitalizations in a population with CHD is for cardiovascular surgery. In many 
cases, a singular surgical intervention is not sufficient in ameliorating the adverse 
repercussions of the defect, with 58% of individuals undergoing a reoperation.59 
Reoperations are most common in those with outflow tract lesions, CoA or ToF.60  
 While surgical interventions are both necessary and regularly induce positive 
results, and while surgery can mitigate mortality and morbidity that is associated with 
CHDs, surgical interventions induce their own spectrum of repercussions. The surgeries 
required to correct a complex CHD are often multiple, generating debilitating effects and 
compromising qualify of life.22 For example, in a multi-institutional (n=11) study of 556 
patients with surgically repaired TOF, 43.3% presented with arrhythmia; conversely, in a 
study of children who underwent arterial switch operations for TGA, minimal excess of 
rhythm disturbances were noted.61, 62  
 Non-operative, minimally invasive interventions may also be indicated in patients 
with less severe CHDs. Specifically, via catheterization, ASD, VSD and PDA may be 
closed in cases where such a procedure is warranted. Given that catheterization is a less 
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intense procedure, complications are usually minimal. In a study comparing the outcomes 
of patients with ASD who underwent transcatheter or surgical closure of secundum ASD, 
complication rate was lower and hospital stay was shorter in those who had closure via 
catheter; however, closure success rate was 95.7% in those who underwent the catheter-
based intervention, while it was 100% in those who had surgery.63  
 While some CHDs may be complex, allowing for postpartum detection, other, 
more simple lesions may present later in life, with discovery regularly prompted by the 
development of other cardiovascular conditions.64 Therefore, treatment of a CHD is not 
specific to infancy or adolescence. A single center study in Norway found that 33.1% of 
infants undergo surgical or catheter-based intervention in response to the defect.65 
Conversely, in a 5-year follow-up study of adults with CHD, 19% of adult patients 
underwent surgery or a catheter-based intervention during this period, a majority of 
which were for closure of an ASD.66 While surgery for CHD may occur at any age, age at 
surgical intervention carries with it a differential risk; studies have shown that closure of 
ASD, a minor form of CHD, carries more risks with it as the patients get older.67, 68  
 
Treatments and Medicine Associated with Longer Lifespan  
 While CHD used to be associated with a large risk of mortality, advances in 
modern medicine and surgical techniques have led to a decline in the mortality of patients 
presenting with these conditions.30 It is now estimated that approximately 85% of 
individuals with CHD will survive into adult.69 More recent, and perhaps more striking, 
estimates indicate that 90% of individuals with severe CHD will live until the age of 18, 
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with a study indicating that there has been a mortality decrease of 71%  and 50% among 
patients with  TGA and ToF, respectively.70 71 
 
Impact of Pregnancy in an Individual without CHD  
 Pregnancy in an individual unaffected by CHD poses several health risks to the 
mother due to the necessary alterations in cardiac function to supply adequate blood to 
the developing fetus (Figure 5). Given that stroke volume (SV) and heart rate (HR) both 
increase during pregnancy72, cardiac output (CO) can increase by 45% as early as week 
24 pregnancy and remains elevated until partum.73  Blood volume increases by 40% by 
the end of pregnancy, with a rise in red blood cell mass and plasma volume, leading to a 
pregnancy-specific anemia.72 Moreover, these hemodynamic changes seem to persist not 
only through pregnancy, but they extend into the post-partum period as well. Specifically, 
the increase in SV, CO, and end diastolic volume all persist at least 52 weeks post-
partum.74 As a result of these changes, conditions such as hypertension are common 
during pregnancy, a condition which underlies obstetric death in 14% of cases.75, 76 Thus, 
the question arises of how these physiologic challenges of pregnancy impact those 
mothers with a history of CHD.  
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Figure 5. Hemodynamic changes during pregnancy (A), peripartum (B) and 
postpartum (C) [BC, between contractions; Peak, at the peak of contraction] 77 
During pregnancy, cardiac output increases as a product of both an increase in heart rate 
and stroke volume. During the peripartum period, cardiac output rises during the peak of 
contraction and falls between contractions, however, it remains elevated over baseline. 
After delivery, cardiac output returns to normal within two weeks, however stroke 
volume persists to be elevated, while heart rate is attenuated, compared to baseline.  
 
SPECIFIC AIM 
The aim of this thesis is two-fold. The first aim addresses the experience of the mother, 
specifically focusing on how pregnancy impacts a woman with CHD. Current 
understanding of the risks of pregnancy among women with CHD will be presented and 
discussed, as well as the impact that the pregnancy has on the woman’s post-partum 
health condition (cardiac capacity, alterations in cardiac status, obstetric complications 
and overall health). 
 The second aim is to explore the impact of the mother’s CHD on the child’s 
health. Provided an understanding of changes in maternal hemodynamics, as a product of 
the pregnancy as well as the underlying CHD, the second aim of the thesis will be to 
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determine how alterations in the maternal physiology and uterine environment impact the 
fetus, neonate and developing child.  
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Subsection One: Pregnancy in Women with CHD 
Risk Models for Pregnancy 
 In order to evaluate the risk of pregnancy among women with CHD, it is 
important to develop adequate risk stratification methods to differentiate between those at 
higher risk of adverse events versus populations who are at low risk of complications 
during pregnancy. Several strategies for achieving this have been developed by research 
consortiums invested in understanding the intricacies of cardiac disorders. Two models 
have been developed by research coalitions CARPREG (CARdiac disease in 
PREGnancy) and ZAHARA (Zwangerschap bij Aangeboren HARtAfwijkingen, 
pregnancy in CHD) and a third model has been developed by the World Health 
Organization (WHO). CARPREG and ZAHARA, along with ROPAC (Registry On 
Pregnancy and Cardiac disease) are also the names of the registries/cohorts of individuals 
in which these systems are developed (a model has not yet been developed in ROPAC).  
 The CARPREG risk score was developed by a group of Canadian researchers 
when they conducted a prospective study of 546 women who experienced 599 
pregnancies.78 Utilizing multivariate analysis, the authors identified statistically 
significant predictors of pregnancy-related complications, including cardiac, neonatal, 
pregnancy-induced hypertension and post-partum hemorrhage (Table 4). The risk index 
for cardiac events was then validated, allowing the authors to describe the risk of the 
occurrence of these events based on prevalence of predictors. The estimated risk of 
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cardiac events was described to be 5%, 27% and 75% in women with heart disease who 
presented with 0, 1 or >1 of these predictors. This prospective study validated a previous 
retrospective study from the same coalition of researchers, in which predictors of cardiac 
events were found to be NYHA functional class >II or cyanosis, prior arrhythmia or 
cardiac event (independent predictors in the retrospective study), myocardial dysfunction, 
left heart obstruction, or prior cardiac events.79 It should be noted that these studies 
included all women with heart disease and did not restrict enrollment to congenital status.  
 
Table 4. Multivariate Analysis of Predictors that Increase Risk of Cardiac, Obstetric and Neonatal 
Complications as per the CARPREG Study.  78 
 
 The ZAHARA collaboration is comprised of primarily Dutch researchers who 
developed a novel risk score specific to pregnancy in women with CHDs, in the context 
of the findings of the CARPREG studies. In the ZAHARA study, medical records were 
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reviewed for 1802 women with CHD who experienced 1696 pregnancies leading to 1302 
completed pregnancies.80 This study identified a spectrum of predictors that heightened 
risk of neonatal and cardiac adverse events, but found no significant predictors of 
obstetric events. A modified risk scoring system for cardiac events was presented, which 
included variation in points allotted per predictor, rather than one point per factor as in 
the CARPREG scoring system; a total of eight predictors, including a more specific 
spectrum of factors not included in the CARPREG scoring system, such as the use of 
cardiac medication before pregnancy and valve regurgitation, were identified (Figure 6).  
 
Figure 6. Risk Factors and Risk of Cardiac Complications as Identified in the 
ZAHARA Study.80 The ZAHARA study describes an increase in the prevalence of 
cardiac complications as defined by whether or not the patient presents with one or more 
of the listed conditions. If all conditions are present, a maximum of 12.375 points can be 
given. Among those with none of these risk factors, the prevalence of cardiac 
complications is still 2.9%, whereas among those with factors assigning the individual 
3.51 points or more, the risk of cardiac events is 70%.  
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 Lastly, the World Health Organization (WHO) developed a tool to indicate the 
risk of pregnancy among women with cardiovascular diseases (Table 5). Class I indicates 
that the risk of pregnancy is no higher than the general population and for those 
categorized as Class IV,  pregnancy is contraindicated given the high risk of maternal 
mortality or severe morbidity associated with this event (Figure 7).81 While females with 
mild CHD fall into Class I, individuals with severe defects, including those whom have 
had the defect repaired, fall into Class II or above, indicating that pregnancy may lead to 
severe complications. Thus, although pregnancy in Class II and III is not contraindicated, 
these groups are at a high-risk for complications and emphasis on reducing risk and 
managing conditions is warranted.  
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Table 5. WHO Pregnancy Risk Categorization.  
 
 
 The ZAHARA, CARPREG and WHO method of evaluating risk in pregnancy are 
the most commonly used systems to determine if pregnancy is contraindicated and/or to 
determine potential risk to the mother in populations with cardiac abnormalities. 
However, the validity of these tools across a spectrum of populations is met with variable 
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efficacy in predicting cardiovascular risk. In a Japanese study of 268 pregnancies 
occurring among 190 women with CHD, data indicated that the c-statistic2 was 0.732 
(95% CI: 0.589 – 0.876), 0.737 (95%CI: 0.611 – 0.864) and 0.827 (0.745 – 0.909) for the 
CARPREG, ZAHARA and WHO models, respectively.82 A Chinese study in 730 women 
found similar findings, reporting their results in terms area under the curve 3 (AUC) 
statistics, with the WHO model displaying the best predictive values (AUC:0.71, 95% CI: 
0.67 – 0.76), followed by ZAHARA (AUC: 0.68, 95% 0.60 – 0.75), with the CARPREG 
model least capable of predicting cardiac events (AUC: 0.63, 95% CI: 0.57- 0.71).83 A 
more recent study was in accordance with these findings, but also expanded these results 
by investigating the predictive value of the components of each model, finding that 
systemic ventricular dysfunction, subpulmonary ventricular dysfunction, and symptoms 
of functional incapacity or heart failure were able to predict adverse cardiac events in a 
similar manner to the ZAHARA model.84 Overall, a consensus seems to exist that the 
WHO risk profile most accurately predicts cardiac events in women with CHDs, 
followed by the ZAHARA model, and lastly by the CARPREG model.83-86  
                                                 
2 C-statistic: a numerical representation of the goodness of fit of a model with a binary 
outcome, or in simpler terms, how well a given set of variables can predict whether or not 
something will happen; normally, a value less than 0.5 indicates that the model does not 
predict the outcome well, while a value of 1 indicates that the model perfectly predicts 
the outcome (cardiac adverse events).   
 
3 Area under the curve (AUC): A statistic measuring the ability of a model to 
discriminate between outcomes; the accuracy of model or test to discriminate has been 
divided into categories, with an AUC of >0.9 indicating excellent discrimination, 0.8 to 
0.9 indicating good discrimination, 0.7 – 0.8 indicating fair discrimination, and 0.6 to 0.7 
indicating poor ability for a test to discriminate between those who will and will not 
experience the outcome.  
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 While it seems that the intention of these risk scoring systems is to identify 
potential predictors of cardiovascular events in pregnant women with cardiovascular 
malformations, neonatal outcomes are also regularly reported. In the initial ZAHARA 
study, predictors of neonatal risk factors were twin/multiple gestation, smoking during 
pregnancy, presence of cyanotic heart disease in the mother, mechanical valve prosthesis 
and use of cardiac medication before pregnancy.80 An additional study undertaken prior 
to this one found similar predictors of neonatal adverse events, describing a lack of 
oxygen saturation, smoking history, symptomatic arrhythmia, among others, to elevate 
the risk of neonatal complications. 87  
 
Effect of Pregnancy on Women with Congenital Heart Defects: Cardiovascular 
Complications 
 
 For women with CHD, pregnancy can be even more complicated given the pre-
existing presence of a lesion hindering normal cardiac function. Women with CHD are 
far more likely to experience cardiovascular complications, heart failure and death 
compared to pregnant women with physiologically normal hearts. Studies report variation 
in the percentage of women who experience cardiovascular events, with a 2006 review 
article indicating that cardiovascular events occur in 11% of this patient population. The 
findings of individual studies report cardiovascular events occurring in 6% to 25%, with 
variation due to a variety of employed methodologies, including inclusion criteria, which 
importantly defines whether all forms or only specific forms of CHD are included in a 
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study, and definition of cardiovascular event (which conditions are included in the 
definition).85, 87-91  Age may also be a factor when evaluating risk of cardiac 
complications, as an increase of 7% was noted when comparing pregnancies occurring in 
those greater than the age of 35 versus those under 35 (Risk Ratio 1.07, 95% CI: 1.01 -
1.14).88  
 As underlying structure impacts cardiovascular function and, thus, cardiovascular 
risk, research has also been conducted into specific subgroups of CHD patients. In a 
smaller study, patients with complex anatomy such as those with Fontan circulation, 
demonstrated a 10% risk of cardiovascular complications, while women with repaired 
CoA did not experience any cardiovascular events.92, 93 Risk of cardiovascular events is 
highest in those with complex cyanotic defects, TGA, and Fontan circulation.85 
 The most common cardiovascular complications to occur during pregnancy have 
been described as clinically significant arrhythmia and heart failure.85, 94 On average, 
arrhythmia occurs in 4.5% of women with CHD, according to a meta-analysis.95 This 
finding was similar to a latter large registry-based study on patients with CHD from 
Belgium and the Netherlands, which found arrhythmias to occur in 4.7% of cohort, which 
included 1302 pregnancies among 1802 women with CHD.80  
 The complexity of the underlying condition increases the risk of arrhythmia, with 
6.5% of pregnancies occurring among women with corrected ToF presenting with 
clinically significant arrhythmia.96 Among women with single ventricular palliated CHD, 
arrhythmias occurred in 17.7%.91 The populations which most commonly experience 
arrhythmia are patients who have undergone Fontan repair (16.0% of patients with 
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Fontan repair experienced clinically significant arrhythmia ), patients with TGA (15.6%),  
and AVSD (10.2%).95 Interestingly, in a study encompassing 98 live births occurring 
within a cohort of 54 women with repaired CoA, no women experienced clinically 
significant arrhythmia.93 In 59% of cases of arrhythmia occurring during pregnancy, no 
history of arrhythmia is noted.88 
 Given the stress placed on the heart throughout pregnancy and the potential for 
the underlying CHD to impact the capacity of the heart to respond to this stress, heart 
failure (HF) can also occur throughout pregnancy. Among pregnant women with CHD, 
approximately 4 to 5% will experience HF.85, 95 With regard to differential risk, there 
exists a higher risk of HF in those with pulmonary atresia, with ventricular septal defect 
(20% of those with this condition experienced HF), cyanotic forms of CHD (18.9% of 
those with this condition experienced HF) and Eisenmenger syndrome (21.1% of those 
with this condition experienced HF).95 Thus, the risk of HF, as with other cardiac 
conditions, is associated to the underlying condition (Figure 7). However, one study 
contradicts this association of severity to HF, only 1.6% with women with corrected ToF 
developing HF and a total of 8.1% of this population experiencing any form of 
cardiovascular event.96 It should be noted that risk of HF is not terminated post-partum: 
in a study including patients with both congenital and acquired heart diseases, of all 
patients with HF, 61% only had HF during pregnancy, 23% only had HF after pregnancy, 
and 16% had HF both during pregnancy as well as post-partum.97  
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Figure 7. Prevalence of Congenital Heart Defects among those who experience 
Heart Failure (n=71)97 While this diagram depicts the prevalence of underlying CHD in 
those with HF, it is important to consider that the prevalence of each CHD is not the 
same. ASD and VSD are far more common than Aortic coarctation, but the prevalence of 
HF occurring in these populations is similar, implying that the risk of HF in those with 
complex defects is higher than those with simple or mild defects.   
 
 Other conditions have less severe sequelae or present in a low number of patients. 
Pulmonary edema has been noted to occur in this population; however, few studies have 
included this outcome within their analyses. In a prospective study following 90 
pregnancies, pulmonary edema was found in 19.4% of completed pregnancies.87 A 
slightly smaller, single center study conducted among 34 women experiencing 49 
pregnancies, found a slightly attenuated risk of pulmonary edema, with 16.3% of women 
diagnosed with this condition during pregnancy.98 Interestingly, in this latter study, 
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pulmonary edema was the most prevalent adverse cardiac event, rather than arrhythmia 
or HF.  
  A systematic review described thrombolytic events occurring in approximately 
2% of this population, a majority of which were pulmonary embolisms.95 A latter Dutch 
study found similar incidence with thromboembolic events diagnosed in 4 out of 213 
pregnancies. 85 Among those who have undergone atrial repair of TGA, 
thromboembolism may occur in as many as 4% of pregnant women.99 Conversely, a 
study which utilized a sample of data from an inpatient healthcare database (Healthcare 
Cost and Utilization Project National Inpatient Sample 2012), which included 282 
patients with single ventricles, reported no thrombolytic events in this population.91  
 While the underlying condition may contribute to the risk of cardiovascular 
events throughout pregnancy, treatment course, such as the medications required to 
support the heart (both prior to pregnancy and throughout pregnancy), have been shown 
to impact cardiovascular risk. It is important to consider the potential of medication in 
augmenting the risk of cardiovascular events, given that 9.2% of women with CHD will 
use some form or cardiac medication during pregnancy (diuretic, antiarrhythmic, 
anticoagulant, vasodilator, etc.) 89 Use of cardiac medication pre-pregnancy increased the 
odds of a cardiovascular event among women with corrected ToF, when compared to 
women who had not used any medication [Odds Ratio 11.7, 95% Confidence Interval 
(CI) : 2.2-62.7].96  
 Importantly, myocardial infarction, stroke and death are rare in this population, 
and occur primarily in those with Eisenmenger syndrome or who present with palliated or 
 36 
uncorrected CHD.95 With regard to maternal mortality, a large study undertaken by the 
European Society of Cardiology, which included pregnant women with valvular heart 
disease, ischemic heart disease, CHD or cardiomyopathy found that maternal mortality 
occurred in 1% of the population, an elevated risk over the 0.007% which normally 
occurs in a healthy population.46 One study noted, however, that maternal mortality 
increased to 5% of the population when the mother experienced pulmonary arterial 
hypertension associated with CHD, thus it is important to monitor for this prevalent 
comorbid condition during pregnancy.100  
 
Effect of Pregnancy on Women with Congenital Heart Defects: Obstetric 
Complications  
 Several obstetric complications or events have been researched among pregnant 
women with CHD. Obstetric complications include miscarriage, termination of 
pregnancy, pregnancy-induced hypertension (PIH), preeclampsia, premature rupture of 
membranes, premature labor (<37 weeks gestation), thrombolytic events (which have 
been classified as both cardiac and obstetric in nature), and post-partum hemorrhage 
(PPH). 
 Obstetric complications occur in approximately 5% of pregnancies among women 
with CHDs, with 11% experiencing premature labor, 8.4% experiencing PPH and 5.5% 
experiencing PIH.95 While age may increase risk of cardiac complications, the risk of 
obstetric complications is similar between those aged 35 and over (18% and those under 
35 (13%)(p=0.989).88 Given the presence of a complex lesion, the risk of obstetric 
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complications may be extensive: among women single ventricle palliated CHD, obstetric 
events, such as gestational diabetes, preterm labor, fetal growth restriction and 
hypertension, occurred in 51.8% of patients versus 24.7% in the control population.91 
However, obstetric events are not selective to those with complex defects, as 7% those 
with unrepaired ASD experience pre-eclampsia, while those with repaired ASD 
experience a level of obstetric events similar to the general population.101 Thus, when 
considering obstetric risk, severity of CHD, history of treatment and current treatment 
regimen should be considered.  
 Among women with CHD, approximately 15% (n = 377) of pregnancies will 
terminate by miscarriage.95  When regarding the CHD population, inclusively, the 
variation in prevalence of miscarriage does not waiver drastically; in one study of 496 
pregnancies, a total of 54 miscarriages occurred (11%), of which 44 occurred when the 
gestational age of the fetus was <13 weeks.88 Risk-factors for miscarriage have not been 
fully delineated, however, in a single-center, prospective study, with similar findings, 
(miscarriage occurred in 12.2% of pregnancies), an association was noted between 
maternal hypertension and risk of spontaneous abortion.87 
 However, the risk to specific groups of patients with a given form of CHD may 
waiver from these statistics. In the literature surrounding women who have undergone 
Fontan palliation, miscarriage may occur in up to 66% of pregnancies.92, 102, 103  With 
regard to other complex defects, those with corrected ToF, 19% ended in miscarriage and 
among those with CoA, 17% ended in miscarriage.93, 96 In an additional study on women 
with CoA, only 9% of women had a miscarriage, all of which occurred in the first 
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trimester; the difference in miscarriage between those with native versus unrepaired CoA 
was statistically insignificant.104 
 While cases of miscarriage occur without intention, termination of pregnancy is 
indicated in some populations with CHD, given the risks induced by pregnancy. Induced 
abortions occur in approximately 5% of pregnancies, with estimates increasing to 8%. 87, 
88, 95 The highest proportion of induced abortions seems to occur in patients with mitral 
stenosis and non-operated VSD and those with Fontan circulation. 88, 95 Interestingly, in a 
study on women with CoA, no therapeutic abortions were performed. 104 Presence of 
comorbidity may increase this prevalence, with a cohort of 28 pregnancies among women 
with pulmonary arterial hypertension associated with CHD, experiencing eight induced 
abortions (29%).100  
 While preeclampsia is expected to occur in approximately 2-3% of pregnancies, a 
review of the literature suggests that the CHD population, in general, does not experience 
a higher risk of preeclampsia (3.2% in the healthy population).87, 95 Individuals with 
complex CHDs may present with higher risks of preeclampsia, with a study which 
excluded low-risk CHDs (as in those that were small or fully repaired), reporting 
preeclampsia in 9.5% of cases.90 Specific groups of CHD patients have a heightened risk 
of preeclampsia, namely those with TGA (10.3%), PAVSD (5.9%), CoA (4.9%), and 
pulmonary valve stenosis (4.9%).95 In those with corrected ToF, preeclampsia occurred in 
3.2% of the study population. 96 Moreover, in a study focused on women with CoA, only 
2% of women experienced preeclampsia.104 If severity of CHD indicates risk of pre-
eclampsia, as TGA and CoA are complex defects, milder forms of CHD may present with 
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lower risk. However, in a study comparing the outcome of pregnancy in those with 
repaired versus unrepaired VSD, women with unrepaired VSD presented with a 4-fold 
increased risk of preeclampsia when compared with controls (those without CHD).105 
Preeclampsia also occurs in 3.7% of pregnancies in women over 35 presenting with CHD 
versus 1.5% of those under 35.88 Given the clinical profile of preeclampsia, it follows 
logic that preeclampsia is more prevalent in those with pre-existing hypertension.106  
 Premature labor occurs in 11% of women with CHD, with highest risk among 
those with PAVSD and cyanotic CHD.95  Among women with corrected single ventricle 
defects, risk of pre-term labor was heightened, occurring in 18.1% of pregnancies.91 With 
regard to milder defects, the prevalence of premature labor is higher among those with 
repaired VSD (14.0%) versus unrepaired VSD (3.8%).105 Among  those in which PAH is 
diagnosed, the prevalence of premature labor occurs with similar risk as the general CHD 
population.100  
 While a 2006 review identified that premature rupture of membranes4 occurs in 
3.5% of pregnancies, with half of these cases occurring among patients with TGA, a 
latter study found that premature rupture of membranes occurs in nearly 10% of a 
population with CHD.95, 107 A study including all patients with non-specific heart disease, 
but of which largest proportion of the study population were women with CHD, indicated 
that premature rupture of membranes occurred in 7.4% (n= 63 / 857) women.108 Among 
                                                 
4 Premature ruptures of membranes is also known as “the water breaking” and is the 
process by which the amniotic sac opens; usually, this occurs at the end of term, in 
preparation for delivery, but can occur as a complication earlier in pregnancy  
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those with TGA, specifically, 14.3% of women experienced premature rupture of the 
membrane (n=7 out of 49 completed pregnancies).99  
 Pregnancy-induced hypertension (PIH) occurs in 2.3% to 5.5% of pregnancies, 
with an expected rate of 2.5% to 5.0% occurring in the non-CHD population.46, 95 
However, of those with CoA and TGA, 11.1% and 8.3% of each respective population 
presented with PIH.95  An additional study indicated that PIH occurred in 4.8% of those 
with corrected ToF, which the authors compared to approximately 10% prevalence in a 
healthy population.96 With regard to other forms of hypertension, in a study of 599 
pregnancies among women with both congenital and acquired heart disease, PH was 
found in 25 pregnancies, of which 8 were attributed to the underlying CHD.78 Thus, 
according to this study, approximately 1% of those with CHD will experience PH during 
pregnancy.  
 Post-partum hemorrhage is expected to occur in approximately 8% of women 
with CHD. 88, 95 This risk is lower than that reported in a 20-year single-center, 
retrospective study of 366 pregnancies which identified PPH in 22% of the cohort.109 An 
additional retrospective study also found an increase in the occurrence of PPH, with PPH 
presenting in 14.1% of pregnancies.107 Methods of treatment may also influence the risk 
of PPH,  with a study which sought to identify differential risk patterns in pregnant 
women with biological versus mechanical valve prosthesis reporting that the risk of PPH 
in those with a mechanical valve was 50% versus 22% in those with biological prostheses 
(p=.02).110  
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 Restriction of fetal growth may also occur in women with CHD, with maternal 
cyanosis and reduced cardiac output as predictors of rate of fetal growth.111 In a study of 
women with all forms of heart disease, with 35.2% of the cohort presenting with CHD, 
fetal growth restriction was present in 11.6% of pregnancies (n= 99 out of 857).108 In a 
single-center study of 83 pregnancies, maternal CHD was not associated with fetal 
growth restriction, even when categorizing maternal status by WHO risk classification.112 
 The risk to mother and child can be mitigated via several techniques, including 
method of delivery. In women with CoA, 36% (n=38) of births occurred via caesarean 
section, of which 7 of these procedures were performed for obstetric reasons and the 31 
other were due to cardiovascular risk present in the mother.104 In a cohort of 201 
pregnancies including women with all forms of CHD, 32.7% of women delivered via 
caesarean section, of which nearly half were due to maternal conditions and just over half 
were due to obstetric concerns.113  The prevalence and indication for mode of delivery 
can vary by institution, with a study undertaken at Columbia University Medical Center 
indicating 41%  of deliveries (n=31 out 74) occurred via caesarean section, of which 94% 
(n=29) were due to obstetric complications and the remaining two were due to maternal 
cardiac status.90 Lastly, the indication of mode of delivery is underpinned by the severity 
of the defect, with 82% and 66% of deliveries for those with native and surgically 
corrected ASD, respectively, occurring vaginally, while among those with TGA, 87% of 
women underwent a caesarean delivery.89 In this study, of the 67 (42%) of deliveries via 
caesarean section, 28, 16 and 23 were due to obstetric, festal and maternal cardiac 
conditions, respectively.89  
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 One study sought to determine how age, given both the trend in CHD patients 
living longer as well as a current upward trend in age at first pregnancy, affects the risk of 
complications during pregnancy among a patient population with CHD. When comparing 
two cohorts, those <35 years of age and those >35 years of age, of women with CHD, no 
significant difference was found in the rate of obstetric complications during pregnancy 
(p=.989).88  
 
Cardiovascular Complications Post-Partum 
 While pregnancy enhances cardiac stress, the cardiovascular effects of pregnancy 
may extend beyond delivery. Cardiovascular events after pregnancy occur at a higher 
prevalence than in the general population, with one study indicating that 12% of women 
with CHD experiencing a late cardiac event (>6 months after delivery), with arrhythmia 
and heart failure as the most common events.114  
 Specifically, women who fall into a WHO score of ≥ 3 present with a four-fold 
increase in risk of post-partum cardiac event.115 Moreover, a heightened risk of cardiac 
events occurring after pregnancy is present in the population who experienced a cardiac 
event during pregnancy, when compared to those who did not (Figure 8).  However, the 
risk may not be equally dispersed throughout the post-partum period, with one study 
indicating that 16 out of 21 adverse cardiac events occurring in their patient population of 
pregnant women with CHD (excluding very low risk pregnancies), were diagnosed in the 
6-week period following delivery.90  
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Figure 8. Incidence of adverse cardiac events late after pregnancy stratified by the 
presence or absence of a cardiac event during pregnancy. 114 After five-years of 
follow-up, 27% of those who had an adverse event during pregnancy, sustained an 
additional cardiac event post-partum, whereas 15% of those who did not have a cardiac 
event during pregnancy, experienced a cardiac event post-partum. Cardiac events 
included in this definition are: cardiac death, cardiac arrest, pulmonary edema, sustained 
symptomatic tachycardia requiring treatment, sustained symptomatic bradycardia 
requiring treatment stroke or transient ischemic attack.  
 
 In a multivariate regression analysis, the following variables were found to predict 
maternal cardiac events after pregnancy: NYHA function class > II or resting cyanosis 
[Hazard Ratio (HR): 3.9, 95% CI: 1.2 - 13.0], adverse cardiac events before pregnancy 
and/or pregnancy-related adverse cardiac events (HR: 2.6, 95% CI: 1.3 – 4.9), subaortic 
ventricular dysfunction (HR: 3.0, 95% CI: 1.4  - 6.6), subpulmonary ventricular 
dysfunction and/or significant pulmonary regurgitation (HR:3.2, 95% CI: 1.6 – 6.6 ) and 
left heart obstruction (HR: 2.6 , 95% CI: 1.2  - 5.2).114 In the same study, univariate 
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analysis described a 4-fold increase in risk of cardiovascular events after pregnancy 
among mothers with NYHA functional class >II or cyanosis and a 3-fold increase in risk 
among those who had an adverse event before pregnancy.114 Utilizing these findings, the 
authors were able to delineate a risk-score model, with each predictor equating to one 
point, and described the increased risk of cardiac events after pregnancy among those 
with increasing morbidity during pregnancy (Figure 9).  
 
 
 
Figure 9. Incidence of adverse cardiac events from time of delivery and through five 
years of follow-up. A point is added to the risk score, given the presence of any of the 
following predictors: NYHA class >II and/or resting cyanosis, subaortic ventricular 
dysfunction, subpulmonary ventricular dysfunction and/or significant pulmonary 
regurgitation, left hart obstruction and cardiac events during pregnancy. Cardiac events 
included in this definition are: cardiac death, cardiac arrest, pulmonary edema, sustained 
symptomatic tachycardia requiring treatment, sustained symptomatic bradycardia 
requiring treatment stroke or transient ischemic attack.  The 5-year rate of late cardiac 
events was 7%, 23% and 44% for those with 0, 1 or more than 1 risk score, respectively.  
114 
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Subsection Two: Impact of Maternal CHD on Child 
Neonatal Adverse Events and Outcomes 
 
 While proper counseling and close monitoring of women with CHD throughout 
the pregnancy may reduce the risk of cardiovascular and/or obstetric events, the effect of 
CHD on the fetus, while in-utero, or child, post-partum may not be as easily navigated. 
 In fact, adverse neonatal outcomes occurred in 22.4% - 37.3% of pregnancies among 
women with CHD.85, 87, 98 Moreover, 10.8% of neonates born to women with CHD 
require placement into the neonatal intensive care unit (NICU).90 Adverse events in 
neonates include preterm delivery, small for gestational age (SGA), respiratory distress 
syndrome, intraventricular hemorrhage, and neonatal death.  
 The distribution of neonatal events is not evenly dispersed among all forms of 
CHD. To date, only one extensive meta-analysis of the literature has compiled data from 
studies on pregnancy among women with congenital heart defects. This study found that 
premature delivery was most frequent among women with PAVSD, women with cyanotic 
CHD are most likely to deliver a neonate that is SGA, fetal mortality is rare in all 
populations, except in cases where the mother presents with Eisenmenger Syndrome or 
with cyanotic CHD, and the risk of perinatal mortality is highest among those with 
Eisenmenger Syndrome.95   
  Premature birth is more likely to occur in women with CHD than in a population 
without this spectrum of conditions. Studies which include the full-spectrum of patients 
with CHD have found that preterm birth occurs in 12.2% (a Dutch study undertaken at a 
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series of eight hospitals), 16.6% (a Japanese single-center retrospective study), and 
20.8% (a single-center prospective American study).85, 87, 89 In a study which excluded 
low-risk patients, i.e. those with a completed repaired defect or a clinically insignificant 
(small) defect, preterm birth occurred in 17.7% of patients.90 Interestingly, these risks are 
similar to that of a cohort of 123 births occurring among women with corrected ToF, a 
complex CHD, in which 18% of neonates were delivered preterm; this proportion 
exceeded the comparison “healthy population” cohort, in which preterm birth was 
determined to occur in 10%.96 The highest known/described risk of pre-term birth was 
reported in a small, multi-center study of women with Fontan palliation, in which 
premature birth occurred in 69% of pregnancies.92  
 Prematurity is an independent construct from SGA5, as a premature infant may 
still be of a size appropriate for its weeks of gestation, despite being small relative to a 
child born at full-term. Neonates presenting with SGA are also common in this context, 
with 8% of all neonates born to mothers with CHD exhibiting SGA; 66.7% of these births 
occur with mothers who present with cyanotic CHD and 19.0% occur among mothers 
with TGA.95 A prospective, single-center study encompassing 90 pregnancies among 53 
women (over a 6-year period) found that 8.3% of neonates born to this population were  
SGA while a multicenter prospective study found that 16.0%  neonates born within of the 
213 evaluated pregnancies were SGA.85 Even within a subset of CHD, variation in 
prevalence of SGA may occur, given the medical course of the condition, with women 
                                                 
5 Small-for-gestational age is a term used to describe when a newborn is below the 10th 
percentile of weight that a given neonate at that gestational age should have  
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with repaired VSD presenting with a 4-fold higher risk of giving birth to a SGA child 
than women who had unrepaired VSD (adjusted OR: 4.09; 95%CI: 1.27 – 13.2).105  
Among children born to women with corrected ToF, SGA was prevalent in 18.5% of 
neonates. 96 
 Respiratory distress syndrome is a common condition that occurs with heightened 
frequency in premature infants. Given the elevated risk of prematurity in a population 
born to mothers with CHD, logic would follow that respiratory distress syndrome would 
also present with higher frequency in this population. 116 In a small prospective study 
including 90 pregnancies occurring within a cohort of 53 women, 8.3% of neonates 
experienced respiratory distress syndrome.87 This proportion only slightly exceeded a 
hospital-based study of 123 pregnancies, which found that 6.9% of children experienced 
respiratory distress syndrome; of these, 66.7% were born premature.85  
 A genetic basis for the development of CHD has been described, and thus, it 
follows suit that mothers with CHD have a higher risk of giving birth to children with 
CHD. A large, multi-national study undertaken by the European Society of Cardiology 
found that 3.5% of children born to mothers with CHD presented with some form of the 
congenital defect. However, the diagnosis of CHDs born to women with CHDs may 
occur in up to 9% of children46, 85, 93, 98, 104 When evaluating genetics on a wider spectrum, 
a nationwide cohort study undertaken in Denmark  identified the trend of familial 
clustering of CHDs by calculating a recurrence relative risk of 12.5 (95% CI 10.9 – 14.3) 
in twins of the same sex, a relative risk of 6.93 (95% CI: 5.32 – 9.04) in twins of unlike 
sex, and a relative risk of 3.21 (95% CI: 2.96 – 3.49) when comparing the risk among 
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first-degree relatives (i.e. parent or sibling).117 Therefore, it is evident that a underlying 
genetic cause of CHD may be pertinent in some, but, not all, cases of CHD.  
 Mortality is the offspring of women with CHD is heightened, with 1.7% of 
completed pregnancies (>20 weeks) ending in fetal mortality and 2.3% ending in 
perinatal mortality.95 A Swedish study described stillbirth (after 22 weeks of gestation) 
occurring in 1.2% of a population with CHD (n=5 out of 417 pregnancies).88 In complex 
CHD, the risk of neonatal mortality may be further elevated. In a small study of 123 
completed pregnancies of women with corrected ToF, offspring mortality occurred in 
6.4%, whereas in the healthy comparison cohort, neonatal mortality was estimated to 
occur in 0.9%.96 In a cohort of women with single-ventricle CHD, which includes 
patients with palliated forms of hypoplastic left heart syndrome, tricuspid atresia or 
common ventricle, 87% delivered a live born child, a significantly lower proportion than 
the 98% of live born children that were born to the control cohort, which included women 
without CHD or PH.91  With regard to potential causes of fetal mortality, a large study 
including women with all forms of heart disease, fetal mortality was observed in 1.7% of 
pregnancies, of which 62% were intrauterine death and 21% were due to maternal 
condition.46  Fetal mortality is associated to WHO cardiovascular status, with 0.4%, 
0.6%, 2.8% and 5.7% of pregnancies ending in fetal death among those presenting with 
WHO categorization of 1, 2, 3, or 4, respectively; however, no such association exists for 
neonatal mortality. 46 
 Studies describing intraventricular hemorrhage are limited. One small study found 
that 1.4% of neonates presented with intraventricular hemorrhage, which was supported 
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by an additional small study which found intraventricular hemorrhage to occur in 1.1% of 
neonates. 87, 107  
 Conditions external to the underlying condition have also been researched in their 
effect on offspring. Adverse events occurring in offspring, such as small for gestational 
age, preterm birth, and mortality, were more likely to occur when there was maternal use 
of cardiac medication pre-pregnancy (OR 8.1, 95% CI: 1.4-48.6).96  
 Few studies report on the physical condition of the neonate by use of the Apgar 
score6. The largest known study to evaluate this included 872 patients with CHD, across 
60 hospitals in 28 countries, found that 6.5% of the fetal population had an Apgar score 
<7, an increase over the normal population in which ~1% should have such a score.46 
When categorizing the entire cohort of women, which included various forms of heart 
disease, by WHO score, an Apgar score less than 7 was reported in 4.1%, 10%, 11% and 
17% in neonates born to women who fall into WHO categories of 1, 2, 3, and 4, 
respectively.46 These findings are similar to an additional small, single-center study found 
that 11.1% (n=5/45) of neonates born to mothers with CHD had a 1-minute Apgar score 
of ≤ 5.98  Conversely, a small study, which excluded low-risk pregnancies, determined 
that the median 5-minute Apgar score for children born to mothers with CHD was 9.90   
  
 
                                                 
6 Apgar Score: A method of quickly evaluating neonatal health immediately after birth. 
Developed in 1952, by Virginia Apgar, the score evaluates heart rate, respiration, 
reflexes, muscle tone and color, with points given as 0, 1, or 2, based on the status of the 
neonate. A total of 10 point is given to a healthy child, with no issues within any of these 
categories, with a score 7 or above delineated as normal.  
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DISCUSSION 
 
 Pregnancy is generally well-tolerated in patients with CHD, regardless of the 
severity of the underlying defect. However, there remains a risk of adverse events in both 
mother and fetus, which appear most common among those with complex CHDs. Given 
an increased risk of heart failure and arrhythmia, both during pregnancy and post-partum, 
as well as pregnancy-induced hypertension, cardiovascular health should be monitored in 
all patients. Moreover, pregnancy in the CHD population may be complicated by elevated 
risk of miscarriage, fetal and neonatal death, post-partum hemorrhage and increased 
incidence of premature birth. Lastly, given the extensive stress on the heart during 
pregnancy, mortality risk in the CHD population must be considered. In particular, 
precaution should be taken when pregnancy is considered in the context of a complex or 
unrepaired cyanotic CHD.92, 118 
 One difficulty in evaluating the maternal cardiovascular and obstetric, as well as 
neonatal outcomes, derives from the nature of CHDs: there exists tremendous 
heterogeneity in all types of CHDs. Researchers either recruit the full spectrum of 
patients with CHD88-90, 113, 114 or (usually) those with a specific complex form of CHD.91, 
92, 103, 104 While the latter permits insight into pregnancy in the most high-risk populations, 
data on those with moderate and mild defects is obscured by aggregation into overarching 
studies on CHDs. Fortunately, this discrepancy has been recognized, with researchers 
evaluating pregnancy in low-risk populations, such as those with ASD and VSD (repaired 
versus unrepaired).101, 105 Moreover, a component of our understanding of the impact of 
pregnancy is derived from larger, prospective, multi-center studies; studies which provide 
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more generalizable results. However, a nuance incessant in many of these studies stems 
from the structure of the large databases in which these research studies are undertaken, 
which include patients with both congenital and acquired heart disease.78, 119 Thus, 
nationwide, prospective studies, which will be able to differentiate risk between forms of 
CHD and have sufficient patients in each category to adequately estimate risk are 
warranted.  
 Despite these hindrances in understanding the full spectrum and details of the 
impact of pregnancy in patients with CHD, data agree that maternal and neonatal risks 
exist. Thus, it is essential to evaluate these risks by engaging in pre-pregnancy counseling 
(PPC), supervision of the patient throughout pregnancy, and follow-up with the patient 
and child, post-partum.120 Throughout these proceedings, the American Heart Association 
encourages deviation from usual definitions of simple, moderate or complex CHDs, as 
comorbid conditions, which may alter risk profiles, are not included in such definitions.94 
Regardless, the heightened precision of the modified WHO classification for predicting 
complications in pregnancy, such a tool should be utilized in determining whether 
pregnancy is safe or ill-advised. Those whose health status places them in WHO 
Category IV should avoid pregnancy, and if pregnancy occurs, potential termination of 
the pregnancy must be discussed and may be advised.94 Moreover, extreme precaution 
should be employed in those with severe aortic stenosis, systemic ventricular dysfunction 
or those with who display PH either prior to or during pregnancy.120 
 The effects of PPC are apparent and useful. In a study of women with corrected 
ToF, 9.6% of women who had chosen not to become pregnant did so because of the 
 52 
anticipated risk of cardiovascular events, and half of these women were advised not to 
become pregnant by a cardiologist.96 In a study of women with CoA, 26% of women 
were advised against becoming pregnant due to potential risk to both mother and child.104 
Thus, PPC in high-risk populations may protect these populations from potential morbid 
and mortal conditions. However, while risk evaluation may indicate that pregnancy is 
unwise in those with complex or diverse conditions, some women may still choose to 
pursue pregnancy.103   
 Among those with lower risk, in which pregnancy is generally successful, other 
precautions may be taken to further temper risks to both mother and child. For example, 
delivery method may be considered to minimize risk of harm. As a result, caesarean 
section may be chosen in place of vaginal delivery in response to cardiac or obstetric 
complications.121 While vaginal delivery is recognized to have positive attributes, such as 
decrease of blood loss and a reduction in thrombogenic risk, and induces a more rapid 
recovery, the prevailing theory is that utilization of a caesarean section may avert risk 
from mother and child and is commonly selected in patients with CHD. 122  However, a 
caesarean section may increase risk of thromboembolism and is associated with greater 
risk of PPH, a condition which, regardless of delivery method, occurs with higher 
prevalence in this population with associations to the severity of defect.109, 122, 123 
Moreover, a recent study indicates that a planned caesarean section confers no benefit 
over a planned vaginal delivery.121 While this study indicated significant difference in 
maternal mortality (0.6% in vaginal delivery versus 2% in caesarean section) and heart 
failure (3.9% in vaginal delivery versus 8.4% in caesarean section), importantly, these 
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differences could be due to the indication of caesarean section in those with cardiac and 
obstetric complications. The study also indicated that neonatal outcomes after a planned 
vaginal delivery were better, given a later delivery and thus higher birthweights. Thus, 
the decision to diverge from vaginal delivery, which may forestall obstetric or cardiac 
complications in the moment, may not always be the best course of action. This is 
another topic in need for additional research to clarify the optimal clinical approach.  
 Complications of pregnancy in populations with CHD cannot be fully averted and 
consequences of the underlying defect extend to both mother and child. Miscarriage is 
prominent in this population, with lowest rates among those with simple valvular defects 
and highest rates among those with Fontan circulation and cyanotic defects.95 However, 
the precise causes of this heightened risk of miscarriage is largely unknown. Emotional 
trauma and stress are consistent predictors of miscarriage;124 extending these associations 
physiologically, the systemic stress of a persistent defect may induce miscarriage as a 
protective mechanism for the mother. However, it has also been indicated that hormonal 
signals associated with stress are impeded in pregnancy, in order to protect the fetus from 
maternal stress.125 Thus, further research needs to be undertaken in order to understand 
the precise reason why a high prevalence of miscarriage exists within this population.   
 Restriction of fetal growth may also be a consequence of maternal status, as an 
inverse relationship between cyanosis and fetal growth restriction has been delineated. 111, 
126, 127 Acute consequences of restricted fetal growth are associated with a spectrum of 
disorders, including polycythemia and respiratory distress syndrome, along with various 
metabolic conditions.128  Unfortunately, restriction of fetal growth may have continued 
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consequences into adulthood, with increased risks of cardiovascular disease, stroke, 
diabetes and hypertension well described in this population.129, 130 Thus, the impact of 
maternal CHD on the child’s health may extend beyond partum period and require long-
term follow-up studies to better elucidate any and all associations.  
 Maternal health is also affected by the pregnancy, with both short-term and long-
term sequelae. While maternal mortality is rare, morbidity, such as arrhythmia and heart 
failure are common. One study described that the increased risk of cardiac disease 
associated closely with increases in the number of risk factors present in that 
individual.114 It has been well-described that a primary cardiac event predisposes an 
individual to a second cardiac event, and pregnancy may enhance the likelihood of an 
initial event, which could explain the association between cardiac events during 
pregnancy and cardiac events after pregnancy. However, evaluating risk scores and 
cardiac events over time in pregnant women without a control population, does not 
enable the ability to understand if the increase in risk is due to the pregnancy itself or if it 
arises solely as a product of the presence of comorbid factors. In order to determine the 
long-term effects of pregnancy, prospective studies would benefit from a control 
population of women with CHDs, matched on CHD type and age, in order to more fully 
delineate the long-term impact of CHD on maternal cardiac health status. Regardless, it is 
clear that cardiac events are prominent in this population and precautions should be taken 
to both prevent and adequately treat such events.  
 One way to reduce the risk of cardiac events is via the use of medications which 
support cardiac health. However, the use of medication within patients with CHD is 
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complicated, given the necessity of supporting the heart throughout pregnancy, the need 
to reduce blood pressure, and the potential for clots to occur as a product of both 
arrhythmia and elevated blood pressure. In one study of 213 pregnancies occurring 
among 203 women, 15.5% of women utilized medication intended to reduce potential 
cardiovascular complications prior to pregnancy, of which the largest proportion (12.2% 
of the study population) utilized β-blockers, followed by the use of Vitamin K 
antagonists or heparin (7.0%).85 The use of β-blockers during pregnancy increased the 
risk of neonatal hypoglycemia and increased the risk of fetal growth restriction. The 
overall risk of delivering a SGA neonate increased by 2- to 8-fold.107, 131, 132 Moreover, in 
particular groups, such as those with Fontan circulation, in whom anticoagulation has 
been indicated, there is not enough evidence to guide how to manage thrombotic/embolic 
risk relative to the teratogenic impact of the medication.92 Anticoagulation therapy has 
been associated with adverse neonatal outcomes (OR = 10.0, 95% CI: 1.5 – 91.4).  On the 
other hand, low-molecular weight heparin has been described as relatively safe for both 
mother and child during pregnancy. 133, 134 Therefore, in a population at high risk of 
cardiovascular events, consideration of treatment course should be evaluated in the 
context of risks to both mother and child. This difficult balance speaks to the utility of 
management remaining in the care of those with additional condition-specific 
subspecialty training and the associated high volume of patient care experience. 
 While efforts have been made to understand the multifaceted influences that may 
affect risk to mother and child, gaps in our understanding of the relationship between 
maternal CHD and long-term outcomes for mother and child health remain. Specifically, 
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long-term studies on the impact of maternal CHD on the neurodevelopment of the child 
are lacking; data on neonates are restricted primarily to post-partum information gathered 
while the mother is still hospitalized, and the neonatal health data is regularly limited to 
Apgar scores. Within the CHD patient population, neurological deficiencies have been 
noted to occur with higher prevalence. While some result from genetic conditions, among 
individuals without genetic abnormalities, an increased risk of development delay or 
disorder persists.135, 136 Even among those with mild defects, where surgical interventions 
are regularly unnecessary and clinical presentation may be delayed or absent completely, 
developmental disorders remain (Figure 10). Neurological disorders prevalent in a 
population with CHD extend into psychiatric disorders as well. For example, an 
individual with CHD maintains an elevated risk of either inpatient or outpatient hospital 
contact for a psychiatric condition [1.8-fold for males (95% CI: 1.5–2.1) and 2.5-fold for 
females (95% CI: 2.0 –3.1)].137 
 
 
Figure 10. The prevalence of neurodevelopmental impairment, stratified by form of 
CHD.  136 While mild disability is highest in those with severe defects, mild forms of 
disability still persist in those with mild defects. Severe impairment is highest in those 
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with syndromic forms of CHD and is relatively high in those whose CHDs were palliated 
during childhood. The findings of this study underpin the importance of adequate 
diagnosis and follow-up of all patients with CHD, regardless of treatment and/or 
palliation and severity.   
 
 An underlying hypothesis suggests that sustained hypoxia is a risk to brain 
development. While some studies indicate that within a fetus with CHD, auto-regulatory 
mechanisms alter vascular resistance in order to compensate for deficiencies in blood 
flow resulting from the underlying CHD, this may be insufficient as impaired cerebral 
oxygen levels persist both in-utero and after birth. 138-140 Given that some forms of CHD 
present with cyanosis and potential hypoxia, it is possible that children born to mothers 
with CHD may present with elevated risks of such disorders. Current research on this 
topic is limited to post-partum Apgar scores and long-term follow-up of these patients 
has not yet been undertaken.  
 Perhaps a necessary starting point to begin to understand the maternal-neonatal 
dynamic in populations with CHD is via the development of novel risk models. While 
current risk models, such as the CARPREG, ZAHARA and WHO models adequately 
assess cardiac risk;82-84 these models are insufficient in their ability to define populations 
at high risk for obstetric events or for adverse neonatal outcomes such as maternal 
CHD.85  With the development of such models, a deeper understanding into the 
association of maternal CHD to maternal and neonatal health status, with the additional 
ability to evaluate the impact of factors such a multi-parity, cardiac status, use of 
medication, would allow physicians to provide evidence-based information about cardiac, 
obstetric and neonatal risks prior to pregnancy. Given a growing population of patients 
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with CHD, informed decisions prior to pregnancy and adequate counseling throughout 
pregnancy are essential. 
Specifically, all women with a diagnosed CHD should receive pre-pregnancy 
counseling, ideally via joint efforts of a cardiologist and obstetrician, or should receive 
counseling as soon as the individual is made aware of their pregnancy.77, 120, 141, 142 Prior 
to counseling, a thorough review patient medical records should be undertaken and 
evaluated by these healthcare specialists, with emphasis on understanding the primary 
defect, any surgical or medicinal interventions that have been utilized, and presence of 
comorbid conditions.120  
The counseling sessions should employ a variety of techniques in order to 
evaluate both maternal and fetal risk, within the context of the severity of the underlying 
defect.120 The American Heart Association suggests that women with CHD should 
undergo echocardiography, to have a baseline status of the heart prior to pregnancy and 
perform an exercise stress test, to determine cardiologic functional status.94 Clinical tests 
should be also be utilized to evaluate hemodynamic status, such as blood count and 
electrolyte concentration, and should also test for functionality of the thyroid and liver.94 
Moreover, PPC should also include consideration of any necessary medical or surgical 
interventions that may need to take place prior to pregnancy, in order to minimize risk to 
mother and fetus, which may be employed both to directly treat the underlying defect or 
to treat or prevent associated conditions, such as arrhythmia and hypertension.120   
Monitoring of the pregnancy should also occur throughout the 9-month period, 
consulting with various healthcare professionals, including cardiologists, hematologists, 
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obstetricians, neonatologists, anesthetists and midwives.120, 141 At each antenatal visit, it is 
suggested that blood pressure and heart rate are taken, heart rhythm is assessed, 
auscultation of heart and lung sounds is performed, oxygen saturation is measured, and 
urine be evaluated for proteinuria and fetal growth should be determined.141 
In order to ensure safety of both mother and child, delivery should take place at a 
specialized care center, with the aforementioned specialized staff available throughout 
the process of birth.94 Indications for method of delivery are primarily guided by obstetric 
events or complications, and vaginal delivery is usually recommended.120, 141 After 
delivery, active management is indicated in all women with CHD, which may include 
administration of oxytocin and cord clamping.141 In the post-partum period, monitoring 
of these patients should continue for 24-48 hours post-partum, as hemodynamic 
alterations occur regularly in this period. Lastly, patients should schedule regular clinical 
visits for anywhere between 6 weeks and 6 months, post-partum, dependent on the 
resolution of hemodynamic changes associated with pregnancy.94 By undertaking these 
measures, prior to pregnancy and continued throughout the post-partum period, risk to 
mother and child may be mitigated and successful pregnancies can occur among women 
with a variety of CHDs.  
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CONCLUSION 
 The effect of maternal CHD on mother and child is complex, with important 
factors including category and severity of CHD, presence of other morbidities and use of 
medication. However, given successes that have enabled this population to live into a 
reproductive age, counseling and monitoring pregnancy and offspring outcomes is 
increasingly important. Greater understanding of how the mother’s condition affects the 
child is desired, such that preventative measures may be pursued. Overall, it is an 
achievement that a greater proportion of women with congenital heart disease are able to 
deliver healthy children with minimal risk to herself.   
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APPENDIX A: Simple Definitions of Common Congenital Heart Defects According to 
the American Heart Association 143 
 
Type of Defect Description of Defect 
Aortic Valve Stenosis (AVS) A valve from the heart to the body that 
does not properly open and close and may 
also leak blood. When the blood flowing 
out from the heart is trapped by a poorly 
working valve, pressure may build up 
inside the heart and cause damage. 
 
Atrial Septal Defect (ASD) 
 
A "hole" in the wall that separates the top 
two chambers of the heart. 
This defect allows oxygen-rich blood to 
leak into the oxygen-poor blood chambers 
in the heart. ASD is a defect in the septum 
between the heart's two upper chambers 
(atria). The septum is a wall that separates 
the heart's left and right sides. 
Coarctation of the Aorta (CoA) 
 
A narrowing of the major artery (the 
aorta) that carries blood to the body. 
This narrowing affects blood flow where 
the arteries branch out to carry blood 
along separate vessels to the upper and 
lower parts of the body. CoA can cause 
high blood pressure or heart damage. 
Complete Atrioventricular Canal defect 
(CAVC) 
 
 
A large hole in center of the heart 
affecting all four chambers where they 
would normally be divided. When a heart 
is properly divided, the oxygen-rich blood 
from the lungs does not mix with the 
oxygen-poor blood from the body. A 
CAVC allows blood to mix and the 
chambers and valves to not properly route 
the blood to each station of circulation 
 
d-Transposition of the great arteries 
 
 
A heart in which the two main arteries 
carrying blood away from the heart are 
reversed. 
A normal blood pattern carries blood in a 
cycle: body-heart-lungs-heart-body. 
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When a d-transposition occurs, the blood 
pathway is impaired because the two 
arteries are connecting to the wrong 
chambers in the heart. 
This means that the blood flow cycle is 
stuck in either: 
body–heart –body (without being routed 
to the lungs for oxygen) or 
lungs–heart–lungs (without delivering 
oxygen to the body) 
Without surgery, the only way to survive 
this condition temporarily is to have 
leakages that allow some oxygen-rich 
blood to cross into the oxygen-poor blood 
for delivery to the body. A hospital 
facility can also catheterize a patient until 
corrective surgery can be performed. 
Ebstein's Anomaly 
 
 
A malformed heart valve that does not 
properly close to keep the blood flow 
moving in the right direction. Blood may 
leak back from the lower to upper 
chambers on the right side of the heart. 
This syndrome also is commonly seen 
with ASD (or a hole in the wall dividing 
the two upper chambers of the heart). 
 
I-transposition of the great arteries 
 
 
A heart in which the lower section is fully 
reversed. 
This malformation of the heart causes a 
reversal in the normal blood flow pattern 
because the right and left lower chambers 
of the heart are reversed. The I-
transposition, however, is less dangerous 
than a d-transposition because the great 
arteries are also reversed. This "double 
reversal" allows the body to still receive 
oxygen-rich blood and the lungs to still 
receive the oxygen-poor blood. 
 
Patent Ductus Arteriosis (PDA) 
 
 
An unclosed hole in the aorta. 
 63 
Before a baby is born, the fetus's blood 
does not need to go to the lungs to get 
oxygenated. The ductus arteriosis is a hole 
that allows the blood to skip the 
circulation to the lungs. However, when 
the baby is born, the blood must receive 
oxygen in the lungs and this hole is 
supposed to close. If the ductus arteriosis 
is still open (or patent) the blood may skip 
this necessary step of circulation. The 
open hole is called the patent ductus 
arteriosis. 
 
Pulmonary Valve Stenosis  
A thickened or fused heart valve that does 
not fully open. The pulmonary valve 
allows blood to flow out of the heart, into 
the pulmonary artery and then to the 
lungs. 
 
Single Ventricle Defects 
 
 
Rare disorders affecting one lower 
chamber of the heart. The chamber may 
be smaller, underdeveloped, or missing a 
valve. 
 
Total Anomalous Pulmonary Venous 
Connection (TAPVC) 
 
 
A defect in the veins leading from the 
lungs to the heart. 
In TAPVC, the blood does not take the 
normal route from the lungs to the heart 
and out to the body. Instead, the veins 
from the lungs attach to the heart in 
abnormal positions and this problem 
means that oxygenated blood enters or 
leaks into the wrong chamber. 
 
Truncus Arteriosus  
When a person has one large artery 
instead of two separate ones to carry 
blood to the lungs and body. 
In a normal heart, the blood follow this 
cycle: body-heart-lungs-heart-body. When 
a person has a truncus arteriosus, the 
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blood leaving the heart does not follow 
this path. It has only one vessel, instead of 
two separate ones for the lungs and body. 
With only one artery, there is no specific 
path to the lungs for oxygen before 
returning to the heart to deliver oxygen to 
the body. 
 
Ventricular Septal Defect (VSD) VSD is a hole in the wall separating the 
two lower chambers of the heart. 
In normal development, the wall between 
the chambers closes before the fetus is 
born, so that by birth, oxygen-rich blood 
is kept from mixing with the oxygen-poor 
blood. When the hole does not close, it 
may cause higher pressure in the heart or 
reduced oxygen to the body. 
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